GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Affimed NV (OTCPK:AFMDQ) » Definitions » YoY Rev. per Sh. Growth

AFMDQ (Affimed NV) YoY Rev. per Sh. Growth : -92.14% (As of Sep. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Affimed NV YoY Rev. per Sh. Growth?

YoY Rev. per Sh. Growth is the percentage change of Revenue per Share over the past twelve months. Affimed NV's YoY Rev. per Sh. Growth for the quarter that ended in Sep. 2024 was -92.14%.

Affimed NV's Revenue per Share for the three months ended in Sep. 2024 was $0.01.

Affimed NV YoY Rev. per Sh. Growth Historical Data

The historical data trend for Affimed NV's YoY Rev. per Sh. Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Affimed NV YoY Rev. per Sh. Growth Chart

Affimed NV Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
YoY Rev. per Sh. Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only -17.08 11.70 -7.65 -19.39 -80.37

Affimed NV Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
YoY Rev. per Sh. Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -85.82 -96.21 -96.59 -89.11 -92.14

Affimed NV YoY Rev. per Sh. Growth Calculation

YoY Rev. per Sh. Growth is the percentage change of Revenue per Share over the past twelve months.

Affimed NV's YoY Rev. per Sh. Growth for the fiscal year that ended in Dec. 2023 is calculated as:

YoY Rev. per Sh. Growth (A: Dec. 2023 )
=(Revenue per Share (A: Dec. 2023 )-Revenue per Share (A: Dec. 2022 ))/ | Revenue per Share (A: Dec. 2022 ) |
=(0.604-3.077)/ | 3.077 |
=-80.37 %

Affimed NV's YoY Rev. per Sh. Growth for the quarter that ended in Sep. 2024 is calculated as:

YoY Rev. per Sh. Growth (Q: Sep. 2024 )
=(Revenue per Share (Q: Sep. 2024 )-Revenue per Share (Q: Sep. 2023 )) / | Revenue per Share (Q: Sep. 2023 )) |
=(0.011-0.14)/ | 0.14 |
=-92.14 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Affimed NV YoY Rev. per Sh. Growth Related Terms

Thank you for viewing the detailed overview of Affimed NV's YoY Rev. per Sh. Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

Affimed NV Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Affimed NV (OTCPK:AFMDQ) » Definitions » YoY Rev. per Sh. Growth
Comparable Companies
ISCO RGBP EVFM TSOI PBLA BPTH TRVN EMMA QRON WINT VRTX ASX:CSL REGN XKRX:207940 ALNY XBRU:UCB XBRU:ARGX ONC XKRX:068270 BNTX
Traded in Other Exchanges
0HL9:UK
Address
Gottlieb-Daimler-Strabe 2, Mannheim, BW, DEU, 68165
Website
https://www.affimed.com
Affimed NV is a clinical-stage biopharmaceutical company. The company is engaged in discovering and developing targeted cancer immunotherapies. Its product candidates are being developed in the field of immuno-oncology, which represents an approach to cancer treatment that seeks to harness the body's immune defenses to fight tumor cells. It is active in the discovery, pre-clinical and clinical development of antibodies based on its core technology. The Company generates revenues from the provision of research and development services to third parties based on both Group and third party owned intellectual property. Geographically, it derives a majority of revenue from the United States and also has a presence in and Germany.